Impact of Ventricular Catheter Used With Antimicrobial Agents on Patients With a Ventricular Catheter

This study has been completed.
Sponsor:
Information provided by:
Chinese University of Hong Kong
ClinicalTrials.gov Identifier:
NCT00286104
First received: February 1, 2006
Last updated: December 21, 2009
Last verified: July 2009
  Purpose

External ventricular catheters are used for intracranial pressure monitoring and temporary cerebrospinal fluid (CSF) drainage in neurosurgery. The incidence of ventriculostomy-related cerebrospinal fluid infections had been quoted as between 2.2% to 10.4% in the more recent literature. Previous prospective studies in the investigators' unit have shown that the use of dual antibiotics prophylaxis in patients with external ventricular drain was associated with decreased incidence of CSF infection but was complicated with opportunistic extracranial infections. The current practice is to cover with prophylactic dual antibiotics unless guided by microbiology results for all patients with external ventricular drain. In recent years, cerebrospinal fluid shunt catheters impregnated with antimicrobial agents have been available. Experimental studies have shown that they provide protection against staphylococcal aureus and coagulase-negative staphylococci strains for between 42 days and 56 days. Theoretically, they provide the antibiotic prophylaxis locally without the associated complications of systemic antibiotics.

It is hypothesized that the use of antibiotic-impregnated catheters instead of systemic antibiotic prophylaxis will not increase the rate of cerebrospinal fluid infection, will decrease the rate of opportunistic/nosocomial infections and improves the overall outcome in these patients; that would convert into a reduction in treatment cost of these patients.


Condition Intervention Phase
Hydrocephalus
Intracranial Hypertension
Device: Antibiotics-impregnated ventricular catheter (Bactiseal®)
Device: Plain ventricular catheter (Codman EDS II/III)
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: The Impact of Ventricular Catheter Impregnated With Antimicrobial Agents on Infection in Patients With Ventricular Catheter: A Prospective Randomized Study

Resource links provided by NLM:


Further study details as provided by Chinese University of Hong Kong:

Primary Outcome Measures:
  • Cerebrospinal fluid infection rate [ Time Frame: First 30 days ] [ Designated as safety issue: No ]
  • Extracranial infection rate [ Time Frame: First 30 days ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Mortality rate [ Time Frame: At discharge and six months ] [ Designated as safety issue: Yes ]
  • Glasgow Outcome Scale Extended [ Time Frame: At discharge and at six months ] [ Designated as safety issue: No ]

Enrollment: 184
Study Start Date: April 2004
Study Completion Date: June 2009
Primary Completion Date: December 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
Bactiseal ventricular catheter (Rifampicin- and Clindamycin-impregnated)
Device: Antibiotics-impregnated ventricular catheter (Bactiseal®)
Antibiotics-impregnated ventricular catheter (Rifampicin- and Clindamycin-impregnated)
Other Name: Bactiseal
Placebo Comparator: 2
Plain ventricular catheter
Device: Plain ventricular catheter (Codman EDS II/III)
Plain ventricular catheter
Other Name: Codman EDS II/III

Detailed Description:

Objective:

  1. To assess the cranial and extracranial infection rate of systemic antibiotic prophylaxis versus antibiotics-impregnated catheter.
  2. To assess the patients' outcome and carry out cost analysis for systemic antibiotic prophylaxis versus antibiotics-impregnated catheter.

Design: Prospective randomized controlled trial

Hypothesis: The use of antibiotics-impregnated catheter instead of systemic antibiotic prophylaxis will not increase the rate of cerebrospinal fluid infection, will decrease the rate of opportunistic/nosocomial infection and improves the overall outcome in these patients; that would convert into a reduction in treatment cost of these patients.

Method: After ventricular catheter insertion, patients will be randomized into one of the two groups:

  1. Periprocedural antibiotics: Only ie Unasyn and Rocephin and insertion of the antibiotics-impregnated ventricular catheter.
  2. Periprocedural antibiotics and prophylactic dual antibiotics ie Unasyn and Rocephin and insertion of ventricular catheter without impregnation of antibiotics.

Primary outcome variable: Cerebrospinal fluid infection and extracranial infection.

Sample size: We aim to recruit a total of 180 patients with 90 patients in each arm and expect to complete patient recruitment in 2-3 years. The calculation is based to detect a difference of nosocomial infection rate between 20% and 40%, with 5% level of significance and 80% power.

Projected results and significance:

The project has a good chance to be the first clinical study to the outcome and cost impacts of antibiotic-impregnated ventricular catheter.

  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients with external ventricular drain inserted
  2. Patients with external ventricular drain in-situ planned for at least 5 days

Exclusion Criteria:

  1. Known CSF infection including meningitis
  2. Known sepsis
  3. Uncorrected coagulopathy
  4. No consent available
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00286104

Locations
China, Hong Kong
Division of Neurosurgery, Prince of Wales Hospital, Chinese University of Hong Kong
Hong Kong, Hong Kong, China, 852
Sponsors and Collaborators
Chinese University of Hong Kong
Investigators
Principal Investigator: George KC Wong, FRCSEd(SN) Chinese University of Hong Kong
Study Director: George KC Wong, FRCSEd(SN) Chinese University of Hong Kong
  More Information

No publications provided

Responsible Party: George KC Wong, Division of Neurosurgery, The Chinese University of Hong Kong
ClinicalTrials.gov Identifier: NCT00286104     History of Changes
Other Study ID Numbers: CREC-PWS-002
Study First Received: February 1, 2006
Last Updated: December 21, 2009
Health Authority: Hong Kong: Department of Health

Keywords provided by Chinese University of Hong Kong:
Ventriculitis
External ventricular catheter
Antibiotic-impregnated

Additional relevant MeSH terms:
Hydrocephalus
Hypertension
Intracranial Hypertension
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases
Anti-Infective Agents
Anti-Bacterial Agents
Antibiotics, Antitubercular
Therapeutic Uses
Pharmacologic Actions
Antitubercular Agents

ClinicalTrials.gov processed this record on August 19, 2014